These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35158141)

  • 1. Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir.
    Ramzy S; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 May; 272():121012. PubMed ID: 35158141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.
    Ahmed OA; Elsebaey MA; Fouad MHA; Elkadeem M; Badawi R; Khayyal A; Soliman S; Negm MS; Abd-Elsalam S
    Infect Disord Drug Targets; 2020; 20(3):389-395. PubMed ID: 30569878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simeprevir and sofosbuvir for treatment of hepatitis C infection.
    Chopp S; Vanderwall R; Hult A; Klepser M
    Am J Health Syst Pharm; 2015 Sep; 72(17):1445-55. PubMed ID: 26294237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.
    Eletreby R; Elakel W; Said M; El Kassas M; Seif S; Elbaz T; El Raziky M; Abdel Rehim S; Zaky S; Fouad R; Gamal Eldeen H; Abdo M; Korany M; Yosry A; El Serafy M; El-Sayed MH; ElShazly Y; Waked I; Doss W; Esmat G
    Liver Int; 2017 Apr; 37(4):534-541. PubMed ID: 27712017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
    Izzo I; Zanotti P; Chirico C; Casari S; Villanacci V; Salemme M; Biasi L; Festa E; Castelli F
    Infection; 2016 Dec; 44(6):811-812. PubMed ID: 27311809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
    Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
    Buti M; Calleja JL; Lens S; Diago M; Ortega E; Crespo J; Planas R; Romero-Gómez M; Rodríguez FG; Pascasio JM; Fevery B; Kurland D; Corbett C; Kalmeijer R; Jessner W
    Aliment Pharmacol Ther; 2017 Feb; 45(3):468-475. PubMed ID: 27896822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which therapeutic option for hepatitis C virus genotype 1?
    Brochot E; Helle F; François C; Castelain S; Capron D; Nguyen-Khac E; Duverlie G
    Scand J Gastroenterol; 2015 Apr; 50(4):470-8. PubMed ID: 25396710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.
    Smolders EJ; Willemse SB; El-Sherif O; Khoo S; Burger DM
    Ann Hepatol; 2018; 17(3):525-529. PubMed ID: 29735803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
    J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
    Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report.
    Obed A; Jarrad A; Bashir A; Moog G
    Am J Case Rep; 2016 May; 17():357-9. PubMed ID: 27230979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
    J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
    Bourgeois S; Horsmans Y; Nevens F; van Vlierberghe H; Moreno C; Beumont M; Vijgen L; van Eygen V; Luo D; Hillewaert V; Van Remoortere P; van de Logt J; Ouwerkerk-Mahadevan S
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
    Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
    Piñana JL; Serra MÁ; Hernández-Boluda JC; Navarro D; Calabuig M; Solano C
    Transpl Infect Dis; 2016 Feb; 18(1):89-92. PubMed ID: 26485423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
    Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT
    Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.